Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22253695 | 0.89 | TDP1 (0.32) | TDP1 | |
| SCHEMBL22253607 | 0.80 | CHRNB2 (0.34) | TDP1 | |
| SCHEMBL20522844 | 0.71 | KDM4C (0.35) | TDP1 | |
| SCHEMBL20522846 | 0.71 | KDM4C (0.35) | TDP1 | |
| SCHEMBL21930213 | 0.69 | SIGMAR1 (0.42) | TDP1 | |
| SCHEMBL21930565 | 0.69 | SIGMAR1 (0.42) | TDP1 | |
| SCHEMBL23109716 | 0.65 | HPGD (0.33) | — | |
| SCHEMBL23109718 | 0.65 | HPGD (0.33) | — | |
| SCHEMBL23109717 | 0.65 | HPGD (0.33) | — | |
| SCHEMBL26731620 | 0.64 | SIGMAR1 (0.41) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781574-B1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-11498928-B2 | Macrocyclic spiroethers as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-11-15 | — | — | US | disclosed |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2020147802-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498928-B2 | Macrocyclic spiroethers as Mcl-1 inhibitors | MCL1, BCL9, BCL9L | TDP1 3388/4885 |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | MCL1, BCL9, BCL9L | TDP1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.